SCYNEXIS Stock

SCYNEXIS Stock-Based Compensation

The Stock-Based Compensation (SBC) of SCYNEXIS (SCYX) as of Aug 7, 2026 is 3.35 M USD. In the previous year, Stock-Based Compensation (SBC) was 2.62 M USD — a change of 27.52% (higher).

Stock-Based Compensation

3.35 MUSD

YoY

27.52%

Last updated:

Stock-Based Compensation (SBC) of SCYNEXIS is 2026 3.35 M USD. Stock-Based Compensation (SBC) of SCYNEXIS was 2025 2.62 M USD. It decreases by 27.52% higher compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Stock-Based Compensation (SBC) of SCYNEXIS is 3.35 M USD in 2026.

Stock-Based Compensation (SBC) of SCYNEXIS changed from 2.62 M USD to 3.35 M USD, representing a 27.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Cash Flow — SCYNEXIS

All Key Metrics — SCYNEXIS